使用靶向癌-睾丸抗原MAGE-A3的MHC II类限制性T细胞受体治疗转移性癌症患者
该研究评估了表达MHC II类限制性、HLA-DPB1*0401限制性、靶向MAGE-A3的TCR的自体CD4+ T细胞过继回输治疗转移性癌症的安全性和疗效。17例患者接受治疗,在最高剂量组9例中观察到食管癌、尿路上皮癌和骨肉瘤的客观部分缓解,细胞剂量递增阶段1例转移性宫颈癌获持续完全缓解。多数患者出现短暂发热和预期的血液学毒性,无治疗相关死亡。
要点
- 17例转移性癌症患者接受MAGE-A3 TCR转导的CD4+ T细胞过继回输。
- 最高剂量组9例中3例获客观部分缓解:食管癌4个月、尿路上皮癌≥19个月、骨肉瘤4个月。
- 细胞剂量递增阶段1例宫颈癌获持续完全缓解≥29个月。
核心结论
- 结果表明,输注表达靶向MAGE-A3的MHC II类限制性抗肿瘤TCR的基因工程自体CD4+ T细胞具有安全性和疗效。
- 该临床试验扩展了TCR基因治疗对转移性癌症患者的适用范围。
研究设计与样本
- 患者接受淋巴清除预处理方案,随后过继回输经逆转录病毒转导MAGE-A3 TCR的纯化CD4+ T细胞,并联合全身大剂量IL-2。
- 进行了细胞剂量递增,从1×10^7个总细胞开始,以半对数增量递增至约1×10^11个细胞。
- 9例患者在最高剂量水平(0.78至1.23×10^11个细胞)接受治疗,共17例患者接受治疗。
主要发现
- 细胞剂量递增阶段,1例接受2.7×10^9个细胞的转移性宫颈癌患者观察到客观完全缓解(持续≥29个月)。
- 最高剂量组9例中,1例食管癌患者(缓解持续时间4个月)、1例尿路上皮癌患者(持续≥19个月)和1例骨肉瘤患者(缓解持续时间4个月)观察到客观部分缓解。
- 多数患者出现短暂发热和淋巴清除预处理预期的血液学毒性。
- 2例患者出现短暂3级和4级转氨酶升高。
- 无治疗相关死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Adoptive transfer of genetically modified T cells is being explored as a treatment for patients with metastatic cancer. Most current strategies use genes that encode major histocompatibility complex (MHC) class I-restricted T-cell receptors (TCRs) or chimeric antigen receptors to genetically modify CD8+ T cells or bulk T cells for treatment. Here, we evaluated the safety and efficacy of an adoptive CD4+ T-cell therapy using an MHC class II-restricted, HLA-DPB1*0401-restricted TCR that recognized the cancer germline antigen, MAGE-A3 (melanoma-associated antigen-A3). Patients and Methods Patients received a lymphodepleting preparative regimen, followed by adoptive transfer of purified CD4+ T cells, retrovirally transduced with MAGE-A3 TCR plus systemic high-dose IL-2. A cell dose escalation was conducted, starting at 107 total cells and escalating at half-log increments to approximately 1011 cells. Nine patients were treated at the highest dose level (0.78 to 1.23 × 1011 cells). Results Seventeen patients were treated. During the cell dose-escalation phase, an objective complete response was observed in a patient with metastatic cervical cancer who received 2.7 × 109 cells (ongoing at ≥ 29 months). Among nine patients who were treated at the highest dose level, objective partial responses were observed in a patient with esophageal cancer (duration, 4 months), a patient with urothelial cancer (ongoing at ≥ 19 months), and a patient with osteosarcoma (duration, 4 months). Most patients experienced transient fevers and the expected hematologic toxicities from lymphodepletion pretreatment. Two patients experienced transient grade 3 and 4 transaminase elevations. There were no treatment-related deaths. Conclusion These results demonstrate the safety and efficacy of administering autologous CD4+ T cells that are genetically engineered to express an MHC class II-restricted antitumor TCR that targets MAGE-A3. This clinical trial extends the reach of TCR gene therapy for patients with metastatic cancer.
引用
- Lu YC, Parker LL, Lu T, et al. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. J Clin Oncol. 2017. PMID: 28809608. doi:10.1200/JCO.2017.74.5463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。